Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cellectis S.A
CLLS | US
4.27
USD0.18
4.40%
CLLS | US
About Cellectis S.A
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
4.27
Open
4.29
High
4.35
Low
4.14
Cellectis S.A. a clinical stage biotechnological company develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19 an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris France.
View LessCLLS | US
Risk
84.0
Sharpe
1.92
Luna's Score
58/100
Recommendation
Hold
Luna says (CLLS | US)
What's Working
Positive Momentum
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
103.5%1 month
84.0%3 months
73.8%6 months
80.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.29
Debt to equity
0.74
Debt to assets
0.27
Ent. to EBITDA
-3.90
Ent. to rev.
1.32
PEG
-
Other Fundamentals
EBITDA
-77.39M
MarketCap
446.50M
MarketCap(USD)
446.50M
Div. yield
-
Op. margin
-181.11
Erngs. growth
-
Rev. growth
374.90
Ret. on equity
-64.37
Short ratio
20.35
Short perc.
0.44
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.22
Range1M
1.56
Range3M
1.56
Volumes: Market Activity
Rel. volume
0.31
Price X volume
60.39K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.90 | - | Cheaper |
| Ent. to Revenue | 1.32 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.29 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 73.83 | - | Par |
| Debt to Equity | 0.74 | -1.23 | Expensive |
| Debt to Assets | 0.27 | 0.25 | Par |
| Market Cap | 446.50M | - | Emerging |
